UPDATES ON MANAGEMENT OF IRRITABLE BOWEL SYNDROME

Alosetron• 1 st IBS specific medication approved by FDA• 5HT3 ( serotonin ) receptor antagonists• Modulate visceral afferent activity from the GIT• 1 Meta‐analysis14 RCTsmore effective than the comparators in achieving globalimprovement in IBS symptoms (pooled relative risk, 1.60; 95%confidence interval [CI], 1.49‐1.72; I(2) = 0%) and relief ofabdominal pain and discomfort (pooled relative risk, 1.30; 95% CI,1.22‐1.39; I(2) = 22%)Effects of 5‐hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritablebowel syndrome: a systematic review and meta‐analysis of randomized controlled trials. Clin Gastroenterol Hepatol. 2008